肝細胞癌におけるレンバチニブ投与後の血圧上昇は良好な予後のサロゲートマーカーになり得る

• 資料種別: 博士論文
• タイトル: 肝細胞癌におけるレンバチニブ投与後の血圧上昇は良好な予後のサロゲートマーカーになり得る
• 著者・編者: 柴田, 啓佑
• 著者標目: 柴田, 啓佑
• 出版事項: Springer Nature
• 出版年月日等: 2025-06-12
• 出版年（W3CDTF）: 2025-06-12
• 並列タイトル等: Blood Pressure Elevations Post-Lenvatinib Treatment in Hepatocellular Carcinoma: A Potential Marker for Better Prognosis
• 授与機関名: 鹿児島大学
• 授与年月日: 2025-06-12
• 授与年月日（W3CDTF）: 2025-06-12
• 報告番号: 甲総研第792号
• 学位: 博士(医学)
• 本文の言語コード: eng
• 件名標目: Lenvatinib; Onco-Hypertension; VEGF Inhibitors
• 対象利用者: 一般
• 一般注記: 出版タイプ： VoR; 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨; Lenvatinib is a tyrosine kinase inhibitor that effectively inhibits vascular endothelial growth factor signaling and is used for treating hepatocellular carcinoma. However, angiogenesis inhibitors often cause hypertension. Although lenvatinib-induced hypertension has been proposed as a potential surrogate marker for better prognosis, studies on blood pressure elevations and outcomes following lenvatinib initiation are limited. This study included 67 patients who underwent lenvatinib therapy at the Department of Gastroenterology, Kagoshima University Hospital, between May 2018 and December 2023. The median age of the cohort was 71 years, and 82.1% of the patients were male. The median blood pressure at admission was 128/73 mmHg, which significantly increased to 136/76 mmHg the day after lenvatinib administration. Grade 3 hypertension (≥160/100 mmHg) occurred in 37.3% of patients during hospitalization. The median increase in systolic blood pressure from admission to its peak during hospitalization was 26 mmHg. Patients who experienced an increase in blood pressure of ≥26 mmHg were classified into the blood pressure elevation group, which showed a significantly lower mortality rate than that of the blood pressure non-elevation group (35.3% vs. 81.8%, log-rank p = 0.007), even after adjusting for age, sex, disease stage, performance status, and liver reserve function. This study demonstrated that patients who experienced earlier blood pressure elevation after lenvatinib administration had lower overall mortality rates. These findings suggest that blood pressure elevations after lenvatinib initiation may serve as valuable prognostic indicators in patients with cancer undergoing lenvatinib therapy.; Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, Mina Nitta, Shin Kawasoe, Takuro Kubozono, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari & Mitsuru OhishiBlood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosisHypertens Res 48, 1542–1553 (2025)https://doi.org/10.1038/s41440-025-02149-4; The version of record of this article, first published in Hypertension Research, is available online at Publisher’s website: https://doi.org/10.1038/s41440-025-02149-4
• 国立国会図書館永続的識別子: info:ndljp/pid/14551101; https://dl.ndl.go.jp/pid/14551101
• コレクション（個別）: 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• 収集根拠: 博士論文（自動収集）
• 受理日（W3CDTF）: 2025-11-07T22:06:05+09:00
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: http://hdl.handle.net/10232/0002001250
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp